Saul Kivimäe
About Saul Kivimäe
Saul Kivimäe serves as the Executive Director and Head of Pharmacology and Early Discovery at Nektar Therapeutics in San Francisco, California. He has an extensive academic and professional background in biochemistry, molecular biology, and genetics, with a Ph.D. from The Rockefeller University.
Work at Nektar Therapeutics
Saul Kivimäe has served as the Executive Director and Head of Pharmacology and Early Discovery at Nektar Therapeutics since 2016. His role involves overseeing pharmacological research and the early stages of drug discovery. Nektar Therapeutics is known for its innovative approaches in developing therapies for various medical conditions. Kivimäe's leadership contributes to advancing the company's research initiatives in San Francisco, California.
Education and Expertise
Saul Kivimäe holds a Bachelor of Science degree in Biochemistry and Molecular Biology from the University of Tartu, where he studied from 1994 to 1998. He furthered his education at The Rockefeller University, earning a Ph.D. in Genetics and Biochemistry between 1999 and 2005. His academic background provides a strong foundation for his expertise in pharmacology and early drug discovery.
Background
Kivimäe began his career as a Research Scientist at Cold Spring Harbor Laboratory in 1996. He then transitioned to Rockefeller University as a Graduate Fellow from 1999 to 2005, where he focused on advanced research in genetics and biochemistry. Following this, he worked at UCSF as a Postdoctoral Fellow from 2005 to 2012, and later as a Senior Scientist in Bioengineering and Pharmaceutical Sciences from 2013 to 2016, gaining extensive experience in the field.
Professional Experience
Saul Kivimäe has accumulated significant experience in the life sciences sector. His tenure at UCSF included roles as a Postdoctoral Fellow and Senior Scientist, allowing him to develop expertise in bioengineering and pharmaceutical sciences. His previous positions at Cold Spring Harbor Laboratory and Rockefeller University contributed to his foundational knowledge and research skills, which he applies in his current role at Nektar Therapeutics.